Tozinameran

Possibly Marketed Outside US

Approval Year

Substance Class	Nucleic Acid
Nucleic Acid Type	mRNA VACCINE
Nucleic Acid Subtype	TRANSGENE
Sequence Origin	VIRAL
Sequence Type	COMPLETE
Record UNII	5085ZFP6SJ
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

RNA INGREDIENT BNT-162B2

Preferred Name

English

BNT162B2

Preferred Name

English

BNT-162B2

Preferred Name

English

Tozinameran

Official Name

English

Tozinameran [WHO-DD]

Common Name

English

Showing 1 to 5 of 10 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

SMS_ID

300000019018

PRIMARY

INN

11889

PRIMARY

FDA UNII

5085ZFP6SJ

PRIMARY

NCI_THESAURUS

C173055

PRIMARY

CAS

2417899-77-3

PRIMARY

Showing 1 to 5 of 7 entries

Previous1 2Next

Subunit 0

Show entries

Sugar	Site Range	Site Count
D-Ribose (RNA)	1_2-1_4283	4282 / 4283
2'-O-Methyl-Ribose	1_1	1 / 4283

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Linkage	Site Range	Site Count
Phosphate	1_2-1_4283	4282 / 4282

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					GH879E9T89

SARS-COV2 B.1.1.7 VARIANT

TARGET ORGANISM->VACCINE ANTIGEN

Comments:

APPEARS TO HAVE COMPARABLE EFFICACY TO NON-VARIANT STRAIN

Amount:


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->VACCINE ANTIGEN

Comments:

From 7 days after second dose to a median time of 2 months.

Qualification:

EFFICACY

Amount:

95 % (average)


					BP87QBQ8LZ

TOZINAMERAN EXPRESSED SARS COV2 SPIKE-PROTEIN VACCINE ANTIGEN

EXPRESSED PROTEIN->VECTOR

Amount:


					S8835NH3UH

TOZINAMERAN EXPRESSED SARS COV2 PRE-S-PROTEIN VACCINE ANTIGEN

EXPRESSED PROTEIN->VECTOR

Amount:


					5085ZFP6SJ

Tozinameran

TARGET ORGANISM->VACCINE ANTIGEN

Amount:

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					5085ZFP6SJ

Tozinameran

ACTIVE MOIETY

Comments:

Designed to produce neutralizing antibody to the SARS-CoV-2 S glycoprotein. The intention is that such antibodies would protect against SARS-CoV-2 infection and its resulting disease, COVID-19

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

Structural Modifications

Show entries

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
NUCLEOTIDE SUBSTITUTION	[1_1]	5'-TERMINUS			m2-7,3’-OGppp(m1-2’-O)Ap mRNA CAP	VNP8CZY34V
NUCLEOSIDE_SUBSTITUTION		RESIDUE_SPECIFIC			N1-METHYLPSEUDOURIDINE	09RAD4M6WF

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
5'-UTR sequence of the human alpha-globin mRNA with an optimized ʻKozak sequenceʼ	NUCLEIC ACID FEATURE	Site Range 1_1-1_53
SARS-COV2 SPIKE CODING SEQUENCE	NUCLEIC ACID FEATURE	Site Range 1_54-1_3878

Showing 1 to 2 of 2 entries

Previous1Next